Results 61 to 70 of about 2,131 (192)

Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 5, Page 856-866, May 2026.
The current study found no evidence of cumulative increased safety risks with upadacitinib 15 or 30 mg for up to 6 years and over 9000 patient‐years of safety data in adults and adolescents. There were low rates of adjudicated major adverse cardiovascular events, adjudicated thromboembolic events and malignancies. Abstract Background Atopic dermatitis (
Christopher G. Bunick, Alan D. Irvine, Jonathan I. Silverberg, Emma Guttman‐Yassky, Mona Shahriari, Xinghua Gao, Stephan Weidinger, Norito Katoh, Namita Vigna, Deanne M. Dilley, Elvira D'Andrea, Henrique D. Teixeira, Andrew M. Platt, Gweneth F. Levy   +13 more
wiley   +1 more source

Atopic eczema [PDF]

, 2007
A distressed mother attends the clinic with her three year old daughter, who developed an itchy rash. The rash is reddish and affects her face and wrists. The child is restless and has been scratching all night.
Formosa, Marie Claire
core  

Neutrophils promote CXCR3-dependent itch in the development of atopic dermatitis. [PDF]

, 2019
Chronic itch remains a highly prevalent disorder with limited treatment options. Most chronic itch diseases are thought to be driven by both the nervous and immune systems, but the fundamental molecular and cellular interactions that trigger the ...
Barton, Gregory M, Bautista, Diana M, Brem, Rachel B, Brock, Emily C, Deguine, Jacques, Gronert, Karsten, Hill, Rose Z, Kucirek, Natalie, Rifi, Ziad, Schwendinger-Schreck, Jamie, Walsh, Carolyn M, Wei, Jessica   +11 more
core   +1 more source

Another anti-interleukin (IL)-17 inhibitor: is there an advantage of blocking IL-17A and IL-17F? [PDF]

, 2022
Bimekizumab is the fourth biologic inhibiting interleukin (IL)-17 that has been approved for the treatment of plaquetype psoriasis in Europe.
Albrecht, Joerg, Gerdes, Sascha
core   +1 more source

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

JEADV Clinical Practice, Volume 5, Issue 1, Page 67-74, March 2026.
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo, Antonio Torrelo, Eric L. Simpson, Marjolein De Bruin‐Weller, Diamant Thaçi, Norito Katoh, Silvia Sabatino, Andrew Buchanan, Kasia Morawska, Samuel Ogwu, Karen Denning, Jonathan I. Silverberg   +11 more
wiley   +1 more source

Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways [PDF]

, 2015
BACKGROUND: Atopic dermatitis (AD) is a common inflammatory skin disease with limited treatment options. Several microarray experiments have been conducted on lesional/LS and non-lesional/NL AD skin to develop a genomic disease phenotype.
Ewald, David Adrian, Guttman-Yassky, Emma, Krueger, James G., Litman, Thomas, Malajian, Dana, Suárez-Fariñas, Mayte, Tian, Suyan, Wang, Tianjiao, Workman, Christopher T   +8 more
core   +2 more sources

Eczema Monkeypoxicum Following Sexual Transmission Treated With Tecovirimat

JEADV Clinical Practice, Volume 5, Issue 1, Page 250-253, March 2026.
Capsule summary Mpox is a zoonotic infection that may present severe dissemination in patients with pre‐existing dermatoses. We report a 30‐year‐old man with active atopic dermatitis who developed extensive, sexually transmitted mpox with widespread cutaneous involvement consistent with eczema monkeypoxicum.
Andrés Vidal González, Sergio López Alcázar, José Ángel Amat Sánchez, Francisco Vergara Barria, Rosa Feltes Ochoa, Elena Sendagorta Cudos, Pedro Herranz Pinto   +6 more
wiley   +1 more source

Stratum Corneum Ceramide Abnormalities in Atopic Dermatitis: Pathophysiology and Implications for Disease Management

The Journal of Dermatology, Volume 53, Issue 3, Page 380-387, March 2026.
ABSTRACT The stratum corneum, as the outermost layer of the skin, functions as a critical barrier that maintains cutaneous hydration and systemic homeostasis. Among its structural lipids, ceramides constitute the most abundant and diverse component. These molecules are essential for the formation of lamellar structures that secure barrier integrity ...
Takashi Sakai
wiley   +1 more source

Review of Herpes Zoster Occurrence in Patients With Atopic Dermatitis Treated With JAK Inhibitors

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory skin disease that markedly impairs quality of life. Janus kinase inhibitors (upadacitinib, abrocitinib, and baricitinib) are effective therapies for moderate‐to‐severe AD but are associated with viral reactivation, particularly herpes zoster (HZ), due to immunosuppressive effects on interferon ...
Anna Mandecka, Karolina Perlak, Wiktoria Bajek, Wiktor Kruczek, Aleksandra Frątczak, Karina Polak, Bartosz Miziołek, Beata Bergler‐Czop   +7 more
wiley   +1 more source

Kaposi’s varicelliform eruption: a potentially life-threatening complication of atopic dermatitis

European Journal of Case Reports in Internal Medicine
Introduction: Kaposi’s varicelliform eruption (KVE), also known as eczema herpeticum or eczema vaccinatum, is an acute dermatosis that affects patients with chronic dermatopathies.
María Martín-Galache, Ana María Escalona-Gil, Luis Posado-Domínguez, Alejandro Jiménez-Domínguez, Alicia Arévalo-Cenzual, Francisco Javier López-Ávila, Eduardo Consuegra-Llapur   +6 more
doaj   +1 more source